This study describes demographics, thrombotic and bleeding events, mortality, and
anticoagulant use among hospitalized patients with COVID-19 in the United States. Premier …

Background Most symptoms of coronavirus 2019 (COVID-19) are mild; however, some
patients experience cardiovascular complications, including thromboembolic events and …

Introduction We recently reported a high cumulative incidence of thrombotic complications in
critically ill patients with COVID-19 admitted to the intensive care units (ICUs) of three Dutch …

We evaluated the incidence of thrombosis in patients hospitalized with non-COVID-19 acute
viral respiratory illnesses nationwide from 2012 to 2014 and compared this to the incidence …

Background. A prothrombotic state, attributable to excessive inflammation, cytokine storm,
hypoxia, and immobilization, is a feature of SARS-CoV-2 infection. Up to 30% of patients …

Background Cardiovascular complications, including myocardial infarction, ischemic stroke,
and pulmonary embolism, represent an important source of adverse outcomes in …

Background The coronavirus disease 2019 (COVID-19) causes extensive coagulopathy and
a potential benefit of anticoagulation therapy has been documented for prevention of …

Background Studies report hypercoagulability in coronavirus disease 2019 (COVID‐19),
leading many institutions to escalate anticoagulation intensity for thrombosis prophylaxis …

Objective To determine the difference in the rate of thromboembolic complications between
hospitalized coronavirus disease 2019 (COVID-19)–positive compared with COVID-19 …

Background There is no current standardized approach to anticoagulation in patients with
Coronavirus Disease 2019 (COVID-19) while potential bleeding risks remain. Our study …